Home » Newsletters » BioWorld Science

BioWorld Science

June 14, 2004

View Archived Issues

Eszopiclone for insomnia subject of several studies presented at sleep conference

5-HT2a inverse agonists for the treatment of sleep disorders

Novel atrial K+ channel blockers for prevention of recurrence of atrial fibrillation

Cytomodulin promotes collagen transcription and wound healing in mice

VX-950 enters phase I for HCV

Positive opinion for Apidra in E.U.

Eloxatin awarded 2004 Prix Galien in France

Preliminary results from phase II Liprostin trial in peripheral vascular disease

Metabolic offers progress report

AD-452 enters phase IIa study for rheumatoid arthritis

NeuroSearch and Rheoscience collaborate in obesity

Phase I results for RG-2133 in bipolar disorder and depression

New phase II program for KRX-0401

Vanda acquires rights to iloperidone from Novartis

Aphton begins Swiss regulatory submission for G17DT

MediciNova acquires anxiety compound from Mitsubishi

Encouraging phase I results for aminocandin for systemic fungal infections

Kyorin concludes R&D commission contract with The Scripps Research Institute

InterMune achieves many objectives during Q1 2004

Draxis Health highlights first quarter progress

Penwest highlights first quarter developments

Preliminary evidence suggests a good safety profile of MLN-2704 in prostate cancer patients

Good safety and pharmacokinetic profiles of AQ4N in advanced esophageal carcinoma

NBT-287 and resistance to paclitaxel in human tumor cell lines

Chemoprotective effects of AES-14 in breast cancer patients with oral mucositis

New and unique oral delivery system, CAPIC particles, for insulin and other macromolecules

New dual D2/5-HT2A antagonists and their use claimed by Pfizer

Sanwa Kagaku presents GLP-1 analogues suitable for oral or intranasal administration

Novel chemokine receptor modulators identified at Mitsubishi Pharma

HIV SL9-derived peptides and their use in HIV infection prophylaxis

New erythromycin-quinolone conjugates prepared and tested by GSK team

Genzyme researchers claim antigenic gp100 peptides and their use as cancer vaccines

New buprenorphine prodrugs with potential as topical analgesic agents